SYDNEY — All G, a company using precision fermentation to develop recombinant proteins, has received self-affirmed GRAS (Generally Recognized As Safe) status for its recombinant bovine lactoferrin. With the self-affirmed GRAS status achieved, the company said it is planning to apply for GRAS status from the US Food and Drug Administration in 2025.

The company uses its precision fermentation technology to produce a bioequivalent lactoferrin without the cow. The ingredient, the company said, also delivers 98% more purity and equivalent bioactivity to animal-based lactoferrin.

The ingredient may be used in such applications as functional beverages, protein powders, plant-based milks, oral nutrition support and supplements.

“Our proprietary strain is a breakthrough in lactoferrin production,” said Jan Pacas, founder and chief executive officer at All G. “We can now engage with US food and beverage companies to bring stable supply of an affordable, high-purity protein that can either be substituted into existing production processes or used to open up new markets.”